NCT02080364View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

880

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions
Alzheimer's Disease
Interventions
DRUG

Azeliragon

Azeliragon 5mg administered orally, once daily for 18 months

DRUG

Placebo

Placebo administered orally, once daily for 18 months

Trial Locations (115)

2196

Johannesburg

3081

Heidelberg West

3162

Caulfield

3220

Geelong

4222

Southport

6005

West Perth

6009

Nedlands

6529

Saint George

7405

Cape Town

7530

Cape Town

8011

Christchurch

8022

Christchurch

10032

New York

10312

Staten Island

11042

Lake Success

12208

Albany

18705

Plains

19063

Media

19403

Norristown

21208

Baltimore

24901

Charleston

27157

Winston-Salem

27607

Raleigh

28270

Charlotte

28401

Wilmington

29464

Mt. Pleasant

30331

Atlanta

31909

Columbus

32216

Jacksonville

32503

Pensacola

32806

Orlando

33009

Hallandale

33014

Miami Lakes

33016

Hialeah

Miami Lakes

33122

Miami

33137

Miami

33140

Miami Beach

33351

Sunrise

33445

Delray Beach

33449

Lake Worth

33462

Atlantis

34243

Sarasota

34601

Brooksville

34748

Leesburg

37203

Nashville

38018

Cordova

39401

Hattiesburg

40504

Lexington

44122

Shaker Heights

44718

Canton

60640

Chicago

63141

Creve Coeur

66201

Prairie Village

66205

Fairway

73103

Oklahoma City

73118

Oklahoma City

75231

Dallas

76309

Wichita Falls

78229

San Antonio

78232

San Antonio

84123

Murray

85004

Phoenix

85013

Phoenix

85018

Phoenix

85724

Tucson

85741

Tucson

87109

Albuquerque

90706

Bellflower

90806

Long Beach

90807

Long Beach

91206

Glendale

92251

Imperial

92408

San Bernardino

92506

Riverside

92614

Irvine

92626

Costa Mesa

92653

Laguna Hills

92705

Santa Ana

92835

Fullerton

92868

Orange

94114

San Francisco

97210

Portland

97225

Portland

98201

Kirkland

99352

Richland

02459

Newton

02360

Plymouth

01269

Quincy

08540

Princeton

02914

East Providence

02916

East Providence

T2N 4Z6

Calgary

T1B 4E7

Medicine Hat

B4N4K9

Kentville

N7L 1C1

Chatham

N6C 5J1

London

M3B 257

Toronto

J8T 8J1

Gatineau

J4V2J2

Greenfield Park

Unknown

Cork

Dublin

Galway

G20 OAXA

Glasgow

W1G 9RU

London

WC1X 8QD

London

M8 5RB

Manchester

NN5 6UD

Northampton

OX3 7JX

Oxford

CF64 2XX

Penarth

PR2 9HT

Preston

S5 7JT

Sheffield

SO30 3JB

Southhampton

SN3 6BW

Swindon

WA2 8WA

Warrington

Sponsors

Lead Sponsor

vTv Therapeutics
All Listed Sponsors
lead

vTv Therapeutics

INDUSTRY

NCT02080364 - Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease | Biotech Hunter | Biotech Hunter